TESARO (NASDAQ:TSRO) had its price target reduced by Cowen from $125.00 to $80.00 in a report released on Tuesday. Cowen currently has a market perform rating on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the company. HC Wainwright reissued a buy rating and set a $158.00 price objective on shares of TESARO in a report on Monday, November 20th. Piper Jaffray Companies reissued a hold rating and set a $80.00 price objective on shares of TESARO in a report on Tuesday. SunTrust Banks reissued a buy rating and set a $160.00 price objective on shares of TESARO in a report on Friday, November 10th. Zacks Investment Research raised TESARO from a sell rating to a hold rating in a research note on Wednesday, November 8th. Finally, Argus set a $154.00 price target on TESARO and gave the company a buy rating in a research note on Tuesday, November 28th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $152.64.
Shares of TESARO (NASDAQ TSRO) traded up $0.61 during trading hours on Tuesday, hitting $76.23. The stock had a trading volume of 1,024,715 shares, compared to its average volume of 1,653,100. TESARO has a one year low of $74.35 and a one year high of $192.94. The firm has a market cap of $4,150.00, a price-to-earnings ratio of -9.04 and a beta of 1.51. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.73 and a quick ratio of 4.35.
In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96. Following the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 34.60% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the business. Exane Derivatives acquired a new position in TESARO in the third quarter worth $106,000. Nordea Investment Management AB acquired a new position in TESARO in the second quarter worth $167,000. Oppenheimer Asset Management Inc. boosted its stake in TESARO by 3,042.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares in the last quarter. Toronto Dominion Bank boosted its stake in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares in the last quarter. Finally, BB&T Securities LLC acquired a new position in TESARO in the second quarter worth $222,000.
ILLEGAL ACTIVITY NOTICE: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/tesaro-tsro-given-new-80-00-price-target-at-cowen/1799093.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with our FREE daily email newsletter.